Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Artelo Biosciences ( (ARTL) ) is now available.
Artelo Biosciences, Inc. recently terminated two significant agreements. On August 19, 2025, the company ended its Securities Purchase Agreement with certain investors, nullifying the issuance of shares and warrants, and agreed to return any received purchase price. Additionally, Artelo terminated its Consulting Agreement with ABK Labs, Inc., effective August 16, 2025, forfeiting all rights under the agreement without any financial penalties.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 671,990
Technical Sentiment Signal: Buy
Current Market Cap: $12.9M
See more insights into ARTL stock on TipRanks’ Stock Analysis page.